Regeneron Pharmaceuticals
American biotechnology company / From Wikipedia, the free encyclopedia
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.[2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Quick Facts Company type, Traded as ...
Company type | Public |
---|---|
| |
Industry | |
Founded | 1988; 36 years ago (1988) |
Founders | |
Headquarters | Tarrytown, New York, U.S. |
Area served | Global |
Key people | |
Revenue | US$13.12 billion (2023) |
US$4.05 billion (2023) | |
US$3.95 billion (2023) | |
Total assets | US$33.08 billion (2023) |
Total equity | US$25.97 billion (2023) |
Number of employees | 13,450 (2023) |
Website | www |
Footnotes / references [1] |
Close